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Background: Radial artery access has been shown to reduce mortality
and bleeding events, especially in patients with acute coronary syn-
dromes. Despite this, interventional cardiologists experienced in
femoral artery access still prefer that route for percutaneous coronary
intervention. Little is known regarding the merits of each vascular
access in patients stratified by their risk of bleeding.Received for publication November 6, 2019. Accepted January 27, 2020.
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Contexte : Il a ete demontre que l’accès par l’artère radiale reduit la
mortalite et les hemorragies, en particulier chez les patients
presentant un syndrome coronarien aigu. Malgre cela, les cardiologues
interventionnels qui ont acquis de l’experience en matière d’accès par
l’artère femorale prefèrent encore utiliser cette voie lorsqu’ils doivent
pratiquer une intervention coronarienne percutanee. On connaît malBleeding is one of the strongest periprocedural predictors of
mortality in patients receiving percutaneous coronary inter-
vention (PCI).1 In patients with acute coronary syndromes
(ACS), radial access reduces bleeding, vascular complications,
and all-cause mortality compared with femoral access.2-5These findings have been replicated in large cohorts of ran-
domized controlled trials,2-5 such that the radial approach
continues to gain momentum as the default access site for
PCI. Guidelines and consensus statements recommended it as
the preferred vascular access site in ACS patients.6,7
However, many operators continue to perform PCI via the
femoral approach regardless of ischemic syndrome for personal
reasons, such as a lack of experience with radial access, or for
procedural reasons, such as to acquire better guiding catheter
support in scenarios such as left main bifurcations, severe
calcifications, tortuous coronary arteries, rotational atherec-
tomy, and chronic total occlusions. Because the shortcomingll rights reserved.
Methods: Patients from the Global Leaders trial were dichotomized
into low or high risk of bleeding by the median of the PRECISE-DAPT
score. Clinical outcomes were compared at 30 days.
Results: In the overall population, there were no statistical differences
between radial and femoral access in the rate of the primary end point,
a composite of all-cause mortality, or new Q-wave myocardial infarc-
tion (MI) (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.42-
1.15). Radial access was associated with a significantly lower rate of
the secondary safety end point, Bleeding Academic Research Con-
sortium (BARC) 3 or 5 bleeding (HR 0.55, 95% CI 0.36-0.84).
Compared by bleeding risk strata, in the high bleeding score popula-
tion, the primary (HR 0.47, 95% CI 0.26-0.85; P ¼ 0.012; Pinteraction ¼
0.019) and secondary safety (HR 0.57, 95% CI 0.35-0.95; P ¼ 0.030;
Pinteraction ¼ 0.631) end points favoured radial access. In the low
bleeding score population, however, the differences in the primary and
secondary safety end points between radial and femoral artery access
were no longer statistically significant.
Conclusions: Our findings suggest that the outcomes of mortality or
new Q-wave MI and BARC 3 or 5 bleeding favour radial access in pa-
tients with a high, but not those with a low, risk of bleeding. Because
this was not a primary analysis, it should be considered hypothesis
generating.
l’interêt de chacune de ces techniques d’accès vasculaire au regard du
risque d’hemorragie.
Methodologie : Les patients de l’essai GLOBAL LEADERS ont ete
repartis en deux groupes, selon qu’ils presentaient un risque
d’hemorragie faible ou eleve d’après le score PRECISE-DAPT median,
puis les resultats cliniques ont ete compares à 30 jours.
Resultats : Dans l’ensemble de la population, aucune difference sta-
tistiquement significative n’a ete observee entre l’accès radial et
l’accès femoral quant au critère d’evaluation principal, compose de la
mortalite toutes causes confondues et d’un nouvel infarctus du myo-
carde (IM) avec onde Q (rapport des risques instantanes [RRI] de 0,70;
intervalle de confiance [IC] à 95 % : 0,42-1,15). L’accès radial a ete
associe à un taux significativement plus faible de survenue du critère
secondaire d’evaluation de l’innocuite, c’est-à-dire une hemorragie de
type 3 ou 5 selon la classification du BARC (Bleeding Academic
Research Consortium) (RRI de 0,55; IC à 95 % : 0,36-0,84). Lorsqu’on
compare les sujets en fonction du risque d’hemorragie, les critères
d’evaluation de l’innocuite principal (RRI de 0,47; IC à 95 % : 0,26-
0,85; p ¼ 0,012; pinteraction ¼ 0,019) et secondaire (RRI de 0,57; IC à
95 % : 0,35-0,95; p ¼ 0,030; pinteraction ¼ 0,631) sont favorables à
l’accès radial au sein de la population presentant un risque d’hemor-
ragie eleve. Dans la population presentant un risque d’hemorragie
faible, les differences entre l’accès radial et l’accès femoral quant aux
critères d’evaluation de l’innocuite principal et secondaire ne sont
toutefois plus statistiquement significatives.
Conclusions : Selon ces observations, les resultats concernant la
mortalite ou la survenue d’un nouvel IM avec onde Q et le risque
d’hemorragie de type 3 ou 5 selon la classification du BARC indiquent
que l’accès radial serait à privilegier lorsque le risque d’hemorragie est
eleve, mais pas lorsqu’il est faible. Comme il ne s’agissait pas d’une
analyse principale, il convient de considerer ces observations comme
etant generatrices d’hypothèses.
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Volume - 2020of femoral access is largely due to increased bleeding, the
question remains whether femoral access is still associated with
worse clinical outcomes when the patient has a low risk of
bleeding.
The PRECISE-DAPT (Predicting Bleeding Complication
in Patients Undergoing Stent Implantation and Subsequent
Dual-Antiplatelet Therapy) score was initially designed to
evaluate the risk of bleeding in PCI patients receiving dual-
antiplatelet therapy (DAPT).8 It stratified the risk of
bleeding according to age, hemoglobin, leukocytes, creatinine
clearance, and history of bleeding. Patients with a high
PRECISE-DAPT score were shown to have a higher risk of
bleeding and mortality. In the present study, we aimed to
compare clinical outcomes between radial and femoral artery
access according to the risk of bleeding stratified by the
PRECISE-DAPT score, to understand the interaction be-
tween bleeding risk and vascular access site in the outcomes of
contemporary PCI procedures.Methods
Design
The present study is a prespecified subgroup analysis of the
GLOBAL LEADERS trial, which is a prospective, multi-
centre, open-label, randomized controlled trial (ClinicalTrials.
gov Identifier: NCT01813435). In brief, GLOBALLEADERS trials enrolled a total of 15,991 patients at 130
hospitals in 18 countries (Europe, Asia, Brazil, Australia, and
Canada) from July 1, 2013, to November 9, 2015. The study
population consisted of patients scheduled to undergo PCI for
stable coronary artery disease (CAD) or ACS. The full in-
clusion and exclusion criteria and details can be found in
previous reports.9,10 Notably, patients prescribed oral anti-
coagulation therapy were excluded from the trial.
In the GLOBAL LEADERS trial, patients were random-
ized 1:1 to receive either 12-month DAPT or 1-month DAPT
followed by 23-month ticagrelor monotherapy. The present
study examined outcomes from index PCI to 30 days, as in
previous studies of vascular access site.2,3,5,11 During this
period, all patients received DAPT therapy.
The trial was approved by the institutional review board at
each centre and followed the ethical principles of the Decla-
ration of Helsinki. Every patient provided written informed
consent before participation in the trial.
Patients
The patient flow diagram is shown in Figure 1. There were
14,629 participants from the GLOBAL LEADERS trial
included in this study. All of the analyses were performed
according to the access site: femoral or radial.
The patient’s risk of bleeding was calculated with the
PRECISE-DAPT online calculator.8 The distribution of the
PRECISE-DAPT score is shown in Supplemental Figure S2.
The Global Leaders trial randomized 
15991 patients (pts) before PCI
15661 patients underwent PCI 
with radial or femoral access
-23 (0.14%) withdrew consent and requested the deletion 
of their data from the database
-85 (0.53%) did not undergo PCI and were treated with 
medical therapy alone or urgent CABG 
-93 (0.58%) underwent trans-brachial access, 14 (0.08)% 
underwent unsuccessful trans-brachial access
-103 (0.64%) had both accesses site punctured
-13 (0.08%) patients had no details on vascular 
approaches available
-In 1062 (6.6%) patients, data to calculate PRECISE-
DAPT score were missing
7182 pts high bleeding score7447 pts low bleeding score
14629 patients included
5676 pts
Radial access
1771 pts
Femoral access
5109 pts
Radial access
2073pts
Femoral access
Figure 1. Patient flow diagram of the present study. CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
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Bleeding Risk on Outcomes of Vascular AccessWe dichotomized the overall population according to the
median PRECISE-DAPT score of 16, with 7447 patients in
the low (PRECISE-DAPT score < 16) and 7182 patients in
the high (PRECISE-DAPT score  16) bleeding score
groups, respectively.
Outcomes
The event definitions have been reported previously.9 All
clinical events were compared at 30 days. The primary end
point was a composite of all-cause mortality or new Q-wave
myocardial infarction (MI). The key secondary safety end
point was site-reported bleeding assessed according to the
Bleeding Academic Research Consortium (BARC) criteria
(grade 3 or 5).12 Other secondary end points included a
composite end point of all-cause mortality, stroke, or nonfatal
new Q-wave MI and its individual components.9 Other
additional end points include BARC 2 and a composite of
BARC 2, 3, or 5 bleeding events. In the GLOBAL LEADERS
trial, 20% of reported events were checked against source
documents. Composite end points were analyzed hierar-
chically. Individual components of the composite end points
were reported nonhierarchically.
Statistics
Propensity scores (PSs) were calculated13 by including the
variables of demographic characteristics (age, sex, body mass
index), ACS/stable CAD, coexisting medical conditions (dia-
betes, insulin-dependent diabetes, hypertension, hypercho-
lesterolemia, current smoker, previous bleeding, stroke,
peripheral vascular disease, chronic obstructive pulmonary
disease, renal failure, myocardial infarction, PCI, or coronary
artery bypass graft), antiplatelet therapy, PRECISE-DAPT
score, and each component of complex PCI. PSs were
distributed in a range of 0.1 to 0.75. Therefore, no case wasconsidered to have an extreme PS and none were trimmed.
The distribution of PSs are shown in Supplemental Figure S1.
The data were analyzed with the use of R-Project (R
Foundation, Vienna, Austria). Continuous variables are pre-
sented as mean  SD. The differences in baseline character-
istics (Table 1) between the radial and femoral cohorts in each
bleeding risk stratum are presented as mean difference in
continuous variables and absolute risk difference in categoric
variables.
Details of missing data are presented in Supplemental
Table S1. All missing data were considered as missing
completely at random and were filled in the database by
multiple imputations14 for PS computations. Means of 2
continuous variables were compared by means of
independent-sample Student t test or Mann-Whitney U test
as appropriate. The frequencies of categoric variables were
compared by means of Fisher exact test. Survival was esti-
mated with the Kaplan-Meier method, and differences in
survival were evaluated with a log-rank test. Cox propor-
tionality assumptions were checked by the Schoenfeld re-
siduals against the transformed time, and the assumptions
were met in all models. Cox proportional hazard models
adjusted to PS were then used to compare the end points in
different vascular approaches in the low and high bleeding
score population, respectively. A value of P < 0.05 was
considered to be significant.Results
From July 1, 2013, to November 9, 2015, there were
15,991 patients randomized in the GLOBAL LEADERS trial.
Among them 14,629 (91.5%) participants were included and
analyzed in the present study. There were 7447 patients
categorized in the low bleeding score group (PRECISE-DAPT
score < 16; mean score 9.8  3.7) and 7182 patients
Table 1. Characteristics of the patients at baseline
Characteristic
Low bleeding score* High bleeding score*
Radial access (n ¼ 5676) Femoral access (n ¼ 1771) Difference (95% CI) Radial access (n ¼ 5109) Femoral access (n ¼ 2073) Difference (95% CI)
Mean age, y 58.34  8.31 59.40  7.93 0.80 (0.43-1.18) 70.63  8.38 71.39  8.55 0.77 (0.35-1.19)
Male 4763/5676 (83.9) 1476/1771 (83.3) 0.57 (2.55 to 1.41) 3617/5109 (70.8%) 1380/2073 (66.6%) 4.23 (6.61 to 1.84)
Mean body mass index, kg/m2 28.48  4.76 28.13  4.49 0.35 (0.60 to 0.10) 28.01  4.52 27.92  4.49 0.09 (0.32 to 0.14)
Medical history
Diabetes mellitus 1216/5675 (21.4) 385/1769 (21.8) 0.34 (1.86 to 2.54) 1469/5107 (28.8%) 657/2073 (31.7%) 2.93 (0.57-5.29)
Insulin-dependent diabetes mellitus 318/5663 (5.6) 100/1762 (5.7) 0.06 (1.18 to 1.30) 466/5099 (9.1%) 236/2071 (11.4%) 2.26 (0.68-3.84)
Hypertension 3794/5652 (67.1) 1280/1761 (72.7) 5.56 (3.14-7.97) 4031/5099 (79.1%) 1739/2070 (84.0%) 4.95 (3.02-6.89)
Hypercholesterolemia 3799/5499 (69.1%) 1225/1692 (72.4%) 3.31 (0.86-5.77) 3392/4951 (68.5%) 1503/2018 (74.5%) 5.97 (3.67 to 8.27)
Current smoker 1970/5676 (34.7%) 577/1771 (32.6%) 2.13 (4.64 to 0.38) 951/5109 (18.6%) 354/2073 (17.1%) 1.54 (3.48 to 0.40)
Previous stroke 106/5671 (1.9%) 17/1771 (1.0%) 0.91 (1.48 to 0.33) 182/5104 (3.6%) 82/2067 (4.0%) 0.4 (0.58 to 1.38)
Previous peripheral vascular disease 236/5628 (4.2%) 90/1755 (5.1%) 0.93 (0.22 to 2.09) 412/5063 (8.1%) 177/2058 (8.6%) 0.46 (0.96 to 1.89)
Chronic obstructive pulmonary
disease
212/5651 (3.8%) 69/1764 (3.9%) 0.16 (0.87 to 1.19) 340/5089 (6.7%) 140/2066 (6.8%) 0.10 (1.19 to 1.38)
Previous myocardial infarction 1277/5667 (22.5%) 461/1764 (26.1%) 3.60 (1.28-5.92) 1133/5101 (22.2%) 550/2063 (26.7%) 4.45 (2.23-6.67)
Previous PCI 1713/5675 (30.2%) 640/1769 (36.2%) 5.99 (3.46-8.53) 1619/5107 (31.7%) 842/2070 (40.7%) 8.97 (6.50-11.45)
Previous CABG 140/5674 (2.5%) 159/1769 (9.0%) 6.52 (5.13-7.91) 266/5109 (5.2%) 303/2072 (14.6%) 9.42 (7.78-11.06)
Renal failure 23/5676 (0.4%) 9/1771 (0.5%) 0.10 (0.27 to 0.47) 1378/5109 (27.0%) 619/2073 (29.9%) 2.89 (0.57-5.20)
Previous bleeding 0/5676 (0.0%) 0/1771 (0.0%) NA 66/5109 (1.3%) 21/2073 (1.0%) 0.28 (0.81 to 0.25)
Clinical presentation
Stable coronary artery disease 2828/5676 (49.8%) 1050/1771 (59.3%) 9.46 (6.83-12.1) 2494/5109 (48.8%) 1224/2073 (59.0%) 10.23 (7.71-12.75)
Acute coronary syndrome 2848/5676 (50.2%) 721/1771 (40.7%) 2615/5109 (51.2%) 849/2073 (41.0%)
Antiplatelet therapy
Clopidogrel 2546/5676 (44.9%) 924/1771 (52.2%) 7.32 (4.66-9.98) 2280/5109 (44.6%) 1099/2073 (53.0%) 8.39 (5.84-10.93)
Ticagrelor 3130/5676 (55.1%) 847/1771 (47.8%) 2829/5109 (55.4%) 974/2073 (47.0%)
PRECISE-DAPT score 9.74 (3.68) 9.98 (3.70) 0.23 (0.37-0.43) 23.1 (6.67) 24.27 (7.58) 1.16 (0.81-1.51)
Complex PCI 1515/5544 (27.3%) 518/1718 (30.2%) 2.82 (0.36-5.29) 1508/4970 (30.3%) 667/2010 (33.2%) 2.84 (0.42-5.27)
Multivessel PCI 1106/5544 (20.0%) 364/1718 (21.2%) 1.24 (0.96 to 3.44) 1152/4970 (23.2%) 482/2010 (24.0%) 0.80 (1.40 to 3.01)
Lesions treated  3 427/5544 (7.7%) 152/1718 (8.9%) 1.15 (0.37 to 2.66) 431/4970 (8.7%) 180/2010 (9.0%) 0.28 (1.19 to 1.76)
Stents implanted  3 926/5544 (16.7%) 330/1718 (19.2%) 2.51 (0.40-4.61) 893/4970 (18.0%) 401/2010 (20.0%) 1.98 (0.06 to 4.03)
Bifurcation PCI with  2 stents 163/5544 (3.0%) 73/1718 (4.3%) 1.31 (0.26-2.36) 143/4970 (2.9%) 64/2010 (3.2%) 0.31 (0.59 to 1.20)
Total stent length > 60 mm 722/5544 (13.0%) 213/1718 (12.4%) 0.62 (2.42 to 1.17) 692/4970 (13.9%) 280/2010 (13.9%) 0.01 (1.79 to 1.80)
Total stent length, mm 34.91 (24.59) 34.7 (25.79) 0.21 (1.56 to 1.13) 35.75 (25.21) 36.19 (25.63) 0.44 (0.87-1.75)
CABG, coronary artery bypass graft; CI, confidence interval; PCI, percutaneous coronary intervention.
* Patients with PRECISE-DAPT score < 16 were categorized into the low bleeding score stratum and those with PRECISE-DAPT score  16 were categorized into the high bleeding score stratum.
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Figure 2. Kaplan-Meier event rate curves of the overall population compared by vascular access and bleeding risks. Kaplan-Meier curves show 30-
day cumulative incidence of: (A) all-cause mortality or new Q-wave myocardial infarction (MI) and (B) Bleeding Academic Research Consortium
(BARC) 3 or 5 bleeding in radial (blue) and femoral (red) artery approaches; and (C) all-cause mortality or new Q-wave MI and (D) BARC 3 or 5
bleeding in low (blue) and high (red) bleeding score patients.
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Bleeding Risk on Outcomes of Vascular Accesscategorized in the high bleeding score group (PRECISE-
DAPT score  16; mean score 23.4  7.0). Table 1 shows
the baseline characteristics according to bleeding risk and site
of vascular access in each bleeding risk stratum.Outcomes for the overall population compared by
vascular access and bleeding risks
In the overall population, there was no statistical difference
between access sites in the rate of the primary end point of all-
cause mortality or new Q-wave MI (hazard ratio [HR] 0.70,
95% confidence interval [CI] 0.42-1.15; P ¼ 0.159; Fig. 2A).
However, radial access was associated with a significantly lowerrate of the key secondary safety end point of BARC 3 or 5
bleeding (HR 0.55, 95% CI 0.36-0.84; P ¼ 0.005; Fig. 2B).
Compared with the high bleeding score group, patients in
the low bleeding score group had significantly lower rates of
the primary (HR 0.46, 95% CI 0.28-0.77; P ¼ 0.003;
Fig. 2C) and key secondary safety (HR 0.38, 95% CI 0.24-
0.60; P < 0.001; Fig. 2D) end points.
Interaction between vascular access and bleeding risk
Among patients with a high bleeding score, the rates of all-
cause mortality or new Q-wave MI (HR 0.48, 95% CI 0.27-
0.86; P ¼ 0.014) and BARC 3 or 5 (HR 0.55, 95% CI 0.34-
0.89; P ¼ 0.015) were significantly lower in the radial
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Figure 3. Impact of radial or femoral access in low and high bleeding score patients. Kaplan-Meier curves show 30-day cumulative incidence of: (A)
all-cause mortality or new Q-wave myocardial infarction (MI) and (B) Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding in the high
bleeding score patients; and (C) all-cause mortality or new Q-wave MI and (D) BARC 3 or 5 bleeding in the low bleeding score patients.
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Volume - 2020compared with the femoral group (Fig. 3, A and B). In
contrast, in the low bleeding score cohort, no statistical dif-
ferences in the primary (HR 3.12, 95% CI 0.73-13.36;
P ¼ 0.125) or secondary safety (HR 0.70, 95% CI 0.30-1.61;
P ¼ 0.402) end points were observed between radial and
femoral access (Fig. 3, C and D).
Outcomes of propensity scoreeadjusted Cox regression
in the low and high bleeding score population
Propensity scores were calculated with the use of the var-
iables described earlier. The outcomes of PS-adjusted Cox
regression models are presented in Table 2. In the highbleeding score cohort, compared with femoral access, the rates
of all-cause mortality or new Q-wave MI (HR 0.47, 95% CI
0.26-0.85; P ¼ 0.012; Pinteraction ¼ 0.019), all-cause mortality
(HR 0.48, 95% CI 0.26-0.89; P ¼ 0.020; Pinteraction ¼
0.045), the composite end point of all-cause mortality, stroke,
or new Q-wave myocardial infarction (HR 0.51, 95% CI
0.31-0.83, P ¼ 0.007, Pinteraction ¼ 0.033), BARC 3 or 5
bleeding (HR 0.57, 95% CI 0.35-0.95; P ¼ 0.030;
Pinteraction ¼ 0.631), and BARC 2, 3, or 5 bleeding (HR 0.67,
95% CI 0.51-0.89; P ¼ 0.005; Pinteraction ¼ 0.707) were all
significantly lower in the radial access group. The rates of
stroke (HR 0.59, 95% CI 0.31-1.32; P ¼ 0.199; Pinteraction ¼
0.826) did not differ significantly between the access groups.
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Bleeding Risk on Outcomes of Vascular AccessHowever, in the low bleeding score cohort, no significant
difference was observed in any of the aforementioned clinical
outcomes. Interestingly, radial access was associated with a
nonstatistically significant higher rate of all-cause mortality or
new Q-wave MI compared with femoral access.
In addition, we calculated the CRUSADE (Can Rapid
Risk Stratification of Unstable Angina Patients Suppress
Adverse Outcomes with Early Implementation of the ACC/
AHA Guidelines) and ACUITY (Acute Catheterization and
Urgent Intervention Triage Strategy) scores in our studied
population. The distributions of the 3 bleeding scores are
shown in Supplemental Figure S2. Using the same methods
mentioned above (cutoff points at the median of the score),
the cutoff points for low or high bleeding according to the
CRUSADE and ACUITY score were 19 and 9, respectively.
Propensity scores were generated for the same variables, but
the PRECISE-DAPT score was replaced in the model by the
CRUSADE or ACUITY score. In high bleeding score pa-
tients, all-cause mortality or new Q-wave MI was significantly
higher in the femoral access group when the risk of bleeding
was defined using the ACUITY, but not the CRUSADE,
score. BARC 3 or 5 event rates were all significantly higher in
the femoral access group using both scores. In the low
bleeding score patients, in line with the results observed with
the PRECISE-DAPT score, all-cause mortality or new
Q-wave MI and BARC 3 or 5 events rates were not statisti-
cally different between radial and femoral access, as presented
in Supplemental Table S2. The outcomes using a PRECISE-
DAPT score of 25 as the cutoff point comparing low vs high
bleeding risk (because the PRECISE-DAPT study defined
patients with a PRECISE-DAPT score  25 as high bleeding
risk8) are presented in Supplemental Table S3.Discussion
In an “all-comers” population, we showed that rates of all-
cause mortality or new Q-wave MI and BARC 3 or 5 bleeding
after PCI were not significantly different between radial and
femoral access when the patient was at low bleeding risk
(PRECISE-DAPT score < 16), but favoured radial access in
patients with high bleeding risk (PRECISE-DAPT score
 16).
Previous randomized controlled trials that enrolled patients
with ACS or ST-segment-elevation MI showed that radial
access was associated with a reduction in mortality and major
bleeding events.2,5,11 However, in trials that included patients
with ACS and stable CAD, radial access only lowered the
hazards of bleeding,15 not mortality.16,17 The reason for this
discrepancy between coronary syndromes could be because
patients with ACS receive more potent antithrombotic
drugs,18 which invariably increases their bleeding pro-
pensity.18,19 These patients therefore have most to gain from
radial access, which is associated with fewer vascular compli-
cations and less bleeding,4,7 ultimately leading to lower
mortality. In line with trials that enrolled patients with both
ischemic syndromes, we observed that, compared with
femoral access, radial access was not associated with lower
mortality, but did consistently lower the rate of BARC 3 or 5
bleeding events.
To date, guidelines and consensus statement only recom-
mended the radial approach as the preferred vascular access in
8 Canadian Journal of Cardiology
Volume - 2020ACS patients.6,7 However, in daily practice, PCI operators
may consider the femoral artery as the primary vascular access
site for a complex PCI procedure or for other reasons
regardless of coronary syndrome. Under those circumstances,
operators may evaluate bleeding risk before choosing the site
of vascular access. A report using data from the British Car-
diovascular Intervention Society database20 indicated that
radial access was independently associated with reduced 30-
day mortality and that the magnitude of this effect was
related to baseline bleeding risk. In line with that finding, in
an all-comers population in which patients were treated with
contemporary PCI techniques and antiplatelet therapy, we
showed that in patients at low risk of bleeding, using femoral
access did not lead to significantly increased bleeding events.
Nevertheless, in patients at high risk of bleeding, for better
clinical outcomes radial access should always be used when-
ever considered feasible.
The consensus of the Academic Research Consortium for
high bleeding risk concluded that the increased risk of
bleeding in patients with ACS is more likely to be attributable
to more aggressive antiplatelet therapy, rather than the ACS.18
Therefore, the consensus did not consider ACS as a high
bleeding risk criterion.18 In agreement with this, we found
that after adjusting for bleeding risk and concomitant anti-
platelet therapy, there was no interaction between ischemic
syndromes (ACS vs stable CAD) and vascular approaches for
mortality or BARC 3 or 5 events (all-cause mortality or new
Q-wave MI: Pinteraction ¼ 0.740; all-cause mortality:
Pinteraction ¼ 0.711; BARC 3 or 5: Pinteraction ¼ 0.296). In
contrast, after adjustment for ischemic syndromes and anti-
platelet therapy, an interaction between vascular approaches
and bleeding risk remains (Table 2; all-cause mortality or new
Q-wave MI: Pinteraction ¼ 0.019; all-cause mortality:
Pinteraction ¼ 0.045; BARC 3 or 5: Pinteraction ¼ 0.631).
Speculatively, these findings suggest that the superior out-
comes of radial access might be driven not only by the type of
coronary syndrome, but also by the propensity for bleeding of
enrolled patients. These unresolved questions need exploring
in adequately powered clinical studies.
To rank the risk of bleeding in the GLOBAL LEADERS
trial, we used the PRECISE-DAPT score,8 which was devel-
oped to ascertain the balance between ischemic and bleeding
risk/benefit when using short- or long-term DAPT. The
PRECISE-DAPT study included both ACS and stable CAD
patients and censored bleeding events occurring from the
index PCI to day 7 in an effort to eliminate those bleeding
events related directly to the procedure. Besides using the
PRECISE-DAPT score, we also evaluated bleeding risk with
the CRUSADE21 and ACUITY22 scores. The CRUSADE
score was derived in a noneST-segment-elevation MI popu-
lation and attempted to quantify the risk of major in-hospital
bleeding. The ACUITY score included ACS patients and
aimed to stratify major bleeding risk within 30 days after the
index PCI.
None of these aforementioned scores can ideally evaluate
the risk of bleeding in the present analysis. However,
compared with the CRUSADE and ACUITY studies, the
PRECISE-DAPT study included patients with stable CAD or
ACS, as in the GLOBAL LEADERS trial. Although histori-
cally the PRECISE-DAPT study did not include events until
7 days after the index PCI, in our analysis it still satisfactorilyestimated the intrinsic 30-day bleeding risk of each patient
after PCI and therefore suitably differentiated the bleeding
events of each patient as a function of the site of vascular
access (Table 2). Therefore, we feel justified in using the
PRECISE-DAPT score to rank the risk of bleeding in our
study.
Instead of using the 4 strata assessed by the PRECISE-
DAPT study, we dichotomized the overall population into 2
strata by the median PRECISE-DAPT score. The reason
behind this is that for a binary decision such as the choice of
radial or femoral access, dichotomizing the choices into 2
categories might be simpler and more practical for the
practitioner.
Besides using the PRECISE-DAPT score, we also analyzed
the results of the trial according to the CRUSADE and
ACUITY scores. The results of these scores were in line with
the results using the PRECISE-DAPT score, confirming the
robustness of our study conclusions.Limitations
First, although the PS method was performed to try to
estimate the true effect for the different vascular approaches,
the usual deficiencies of observational studies exist, such as the
inability to include all relevant confounders, especially those
not measured, causing bias that cannot be adjusted.
Second, 8.8% of the overall population from the GLOBAL
LEADERS database were not included in the present study
owing to missing data, brachial access, or dual radial-femoral
access.
Third, given the inherent limitations of subanalyses, our
findings can be be interpreted only as hypothesis generating
and cannot make strong inferences or necessitate changes in
practice by professionals.Conclusion
The present findings suggest that the outcomes of mor-
tality or new Q-wave MI and BARC 3 or 5 bleeding were not
significantly different between radial and femoral access in
patients at low risk of bleeding (PRECISE-DAPT score <
16). However, it strongly favoured radial access in patients at
high bleeding risk (PRECISE-DAPT score  16).Funding Sources
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